Author

E. Altunel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 1 Organism:non-human primate· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

S. Cheng· 2 shared S. Y. Kim· 2 shared A. Agarwal· 1 shared A. Lazarides· 1 shared A. Moseley· 1 shared C. Eward· 1 shared D. Hsu· 1 shared D. L. Corcoran· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. Cheng

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A cross-species drug discovery pipeline to identify and validate new treatments for osteosarcoma

J. Somarelli, G. Rupprecht, E. Altunel, E. Flamant, S. R. Rao, D. Sivaraj, A. Lazarides, S. Hoskinson, M. Sheth, S. Cheng, S. Y. Kim, K. Ware, A. Agarwal, M. Cullen, L. Selmic, , D. Hsu

This study develops a cross-species drug discovery pipeline to identify and validate new treatments for osteosarcoma, finding that dual inhibition of proteasome and CRM1 pathways induces synergistic cytotoxicity.

bioRxiv · Oct 19, 2020Cancer Biology

From the clinic to the bench and back again in one dog year: identifying new treatments for sarcoma using a cross-species personalized medicine pipeline

S. Rao, J. A. Somarelli, E. Altunel, L. E. Selmic, M. Byrum, M. U. Sheth, S. Cheng, K. E. Ware, S. Y. Kim, J. A. Prinz, N. Devos, D. L. Corcoran, A. Moseley, E. Soderblom, S. D. Hsu, W. C. Eward

This paper develops a cross-species personalized medicine pipeline using canine sarcomas to identify new treatments, finding proteasome inhibitors initially effective but limited by tumor heterogeneity.

bioRxiv · Jan 10, 2019Cancer Biology